Recombinant Anti-PDGFR beta (phospho Y751) antibody [EPR21744] (ab218534)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR21744] to PDGFR beta (phospho Y751)
- Suitable for: Dot blot, WB
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-PDGFR beta (phospho Y751) antibody [EPR21744]
See all PDGFR beta primary antibodies -
Description
Rabbit monoclonal [EPR21744] to PDGFR beta (phospho Y751) -
Host species
Rabbit -
Tested applications
Suitable for: Dot blot, WBmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- WB: IMR-90 (treated with 50 ng/ml PDGF-BB for 5 minutes), NIH/3T3 (treated with 50 ng/ml PDGF-BB for 5 minutes) and C6 (treated with 50 ng/ml PDGF-BB for 5 minutes) whole cell lysates.
-
General notes
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.2
Preservative: 0.01% Sodium azide
Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EPR21744 -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab218534 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Dot blot |
1/1000.
|
|
WB |
1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 124 kDa).
|
Notes |
---|
Dot blot
1/1000. |
WB
1/1000. Detects a band of approximately 190 kDa (predicted molecular weight: 124 kDa). |
Target
-
Function
Receptor that binds specifically to PDGFB and PDGFD and has a tyrosine-protein kinase activity. Phosphorylates Tyr residues at the C-terminus of PTPN11 creating a binding site for the SH2 domain of GRB2. -
Involvement in disease
Note=A chromosomal aberration involving PDGFRB is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with EVT6/TEL. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).
Note=A chromosomal aberration involving PDGFRB may be a cause of acute myelogenous leukemia. Translocation t(5;14)(q33;q32) with TRIP11. The fusion protein may be involved in clonal evolution of leukemia and eosinophilia.
Note=A chromosomal aberration involving PDGFRB may be a cause of juvenile myelomonocytic leukemia. Translocation t(5;17)(q33;p11.2) with SPECC1.
Defects in PDGFRB are a cause of myeloproliferative disorder chronic with eosinophilia (MPE) [MIM:131440]. A hematologic disorder characterized by malignant eosinophils proliferation. Note=A chromosomal aberration involving PDGFRB is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with ETV6 on chromosome 12 creating an PDGFRB-ETV6 fusion protein.
Note=A chromosomal aberration involving PDGFRB may be the cause of a myeloproliferative disorder (MBD) associated with eosinophilia. Translocation t(1;5)(q23;q33) that forms a PDE4DIP-PDGFRB fusion protein. -
Sequence similarities
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 5 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain. -
Post-translational
modificationsAutophosphorylated. Dephosphorylated by PTPRJ at Tyr-751, Tyr-857, Tyr-1009 and Tyr-1021. -
Cellular localization
Membrane. - Information by UniProt
-
Database links
- Entrez Gene: 5159 Human
- Entrez Gene: 18596 Mouse
- Entrez Gene: 24629 Rat
- Omim: 173410 Human
- SwissProt: P09619 Human
- SwissProt: P05622 Mouse
- SwissProt: Q05030 Rat
- Unigene: 509067 Human
see all -
Alternative names
- Beta platelet derived growth factor receptor antibody
- Beta-type platelet-derived growth factor receptor antibody
- CD 140B antibody
see all
Images
-
All lanes : Anti-PDGFR beta (phospho Y751) antibody [EPR21744] (ab218534) at 1/1000 dilution
Lane 1 : Untreated IMR-90 (human lung fibroblast cell line) whole cell lysate
Lane 2 : IMR-90 treated with 50 ng/ml PDGF-BB for 5 minutes whole cell lysate
Lane 3 : Untreated NIH/3T3 (mouse embryo fibroblast cell line) whole cell lysate
Lane 4 : NIH/3T3 treated with 50 ng/ml PDGF-BB for 5 minutes whole cell lysate
Lane 5 : Untreated C6 (rat glial tumor glial cell line) whole cell lysate
Lane 6 : C6 treated with 100 ng/ml PDGF-BB for 60 minutes whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/20000 dilution
Predicted band size: 124 kDa
Observed band size: 190 kDa why is the actual band size different from the predicted?Expression of PDGFR beta (phospho Y751) is induced by PDGF-BB. The antibody recognizes both the glycosylated and unglycosylated protein (PMID: 9307305).
Exposure:
Lane 1 - 4: 80 seconds
Lane 5 - 6: 180 seconds
Blocking and diluting buffer: 5% NFDM/TBST
-
Dot blot analysis of PDGFR beta (phospho Y751) labeled with ab218534 at 1/1000 dilution.
Lane 1: Human PDGFR beta (phospho Y751) peptide.
Lane 2: Human PDGFR beta non-phospho peptide.Goat Anti-Rabbit IgG H&L (HRP) (ab97051) at 1/100000 dilution was used as secondary antibody.
Blocking and dilution buffer: 5% NFDM/TBST.
Exposure time: 3 minutes.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
Certificate of Compliance
References (3)
ab218534 has been referenced in 3 publications.
- Tang HY et al. PDGFRβ modulates aerobic glycolysis in osteosarcoma HOS cells via the PI3K/AKT/mTOR/c-Myc pathway. Biochem Cell Biol 100:75-84 (2022). PubMed: 34678088
- Guo JQ et al. PDGF-BB/PDGFRβ promotes epithelial-mesenchymal transition by affecting PI3K/AKT/mTOR-driven aerobic glycolysis in Wilms' tumor G401 cells. Cell Biol Int 46:907-921 (2022). PubMed: 35165984
- Song S et al. EGFR/MET promotes hepatocellular carcinoma metastasis by stabilizing tumor cells and resisting to RTKs inhibitors in circulating tumor microemboli. Cell Death Dis 13:351 (2022). PubMed: 35428350